Abstract
AbstractIndividual chemotherapeutic drugs usually suffered drug resistance in the cancer treatment, and the combination therapy has aroused great interest which can reduce the resistance. Glutamine inhibitor (V9302) and chemotherapy drug doxorubicin (DOX) were combined for the first time to construct a pH‐sensitive multi‐mode synergistic treatment system BSA@CDs‐V9302/DOX. The synergistic rate CI value of the drugs was less than 1, indicating the combination therapy showed a synergistic effect on reducing cancerous cell viability. In addition, compared with the high toxicity and rapid release of free drug DOX and the poor solubility of glutamine inhibitor V9302, the BSA@CDs‐V9302/DOX administration system not only retains the pharmacological activity of V9302 and DOX, but also has an excellent time‐dependence which is more suitable for continuous treatment. BSA@CDs‐V9302/DOX drug delivery system has excellent long‐term tracing ability, which has a high application value in biomedical field.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
